Infantile hemangioma is a common childhood tumor composed of disorganized blood vessels and immature endothelial cells. Hemangioma follows a unique life-cycle in which the tumor appears soon after birth and grows dramatically during infancy. This "proliferating phase" is followed by a spontaneous but slow "involuting phase" that begins after age one. By five to eight years of age, most hemangiomas have reached the "involuted phase" at which point the tumor mass has been replaced by a fibrofatty residuum. Our goal is to understand precise cellular context for growth/involution of hemangioma in order to identify relevant biochemical and molecular pathways which will lay a foundation for the identification of drugs or therapies that will provide a safe and fast-acting treatment for children with endangering hemangiomas. During the previous funding period, we identified a stem/progenitor cell from proliferating phase infantile hemangiomas that can form hemangioma-like vascular lesions in immune-deficient mice. We used anti-CD 133-coated magnetic beads to isolate these hemangioma stem cells (HemSCs) from 28 different proliferating phase hemangiomas. In vitro, the HemSCs are fast-growing and exhibit multi-lineage differentiation potential, including endothelial differentiation in response to VEGF-B. In vivo (mice), the cells form functional blood vessels within 7 days. The blood vessels express the immunophenotype of hemangioma - glucose transporter-1 (GLUTl) and the basement membrane-associated protein merosin. After 1 month, the experimentally-formed hemangiomas begin to involute: blood vessels diminish and adipocytes appear, closely following the unique natural history that characterizes human infantile hemangioma. Based on these properties, the cells we identified and isolated are the equivalent of a "hemangioma stem cell" which we call HemSCs. We propose to use these HemSCs to screen FDA-approved drugs with reported anti-angiogenic activity, and for which we know the target is present in HemSCs, for ability to inhibit HemSC proliferation in vitro and hemangioma formation in vivo. We will also analyze effects of mutations discovered by our collaborators in Projects 1 and 3 on the in vitro and in vivo behavior of HemSCs. Finally, we will continue to refine and optimize our in vivo animal model to identify critical factors that drive the proliferative phase of infantile hemangioma.

Public Health Relevance

Project 2 will study stem cells isolated from a common childhood tumor known as infantile hemangioma. We hope to understand how and why these stem cells are disrupted, such that instead of following a normal healthy pathway to become normal cells and tissue, the hemangioma-derived stem cells form a mass of disorganized blood vessels that grows dramatically during infancy. The results from this study may lead to new fast-ar.tinn and Rafpi troatrnPints fnr nhildrfin with Finrlannerinn hPimanninmas.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Program Projects (P01)
Project #
5P01AR048564-10
Application #
8528329
Study Section
Special Emphasis Panel (ZAR1-EHB-F)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
10
Fiscal Year
2013
Total Cost
$446,398
Indirect Cost
$53,508
Name
Harvard University
Department
Type
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Huang, Lan; Nakayama, Hironao; Klagsbrun, Michael et al. (2015) Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells. Stem Cells 33:133-45
Lee, D; Boscolo, E; Durham, J T et al. (2014) Propranolol targets the contractility of infantile haemangioma-derived pericytes. Br J Dermatol 171:1129-37
Dellinger, Michael T; Garg, Nupur; Olsen, Bjorn R (2014) Viewpoints on vessels and vanishing bones in Gorham-Stout disease. Bone 63:47-52
Uebelhoer, Melanie; Natynki, Marjut; Kangas, Jaakko et al. (2013) Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum Mol Genet 22:3438-48
Amyere, Mustapha; Aerts, Virginie; Brouillard, Pascal et al. (2013) Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet 92:188-96
Butler, Matthew G; Dagenais, Susan L; Garcia-Perez, Jose L et al. (2012) Microcephaly, intellectual impairment, bilateral vesicoureteral reflux, distichiasis, and glomuvenous malformations associated with a 16q24.3 contiguous gene deletion and a Glomulin mutation. Am J Med Genet A 158A:839-49
Greenberger, Shoshana; Yuan, Siming; Walsh, Logan A et al. (2011) Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. J Invest Dermatol 131:2467-76
Goujon, Elisa; Cordoro, Kelly M; Barat, Muriel et al. (2011) Congenital plaque-type glomuvenous malformations associated with fetal pleural effusion and ascites. Pediatr Dermatol 28:528-31
Boon, Laurence M; Ballieux, Fanny; Vikkula, Miikka (2011) Pathogenesis of vascular anomalies. Clin Plast Surg 38:7-19
Bowen, Margot E; Boyden, Eric D; Holm, Ingrid A et al. (2011) Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet 7:e1002050

Showing the most recent 10 out of 36 publications